Joyce Peter R, Mulder Roger T, Luty Suzanne E, Sullivan Patrick F, McKenzie Janice M, Abbott Robyn M, Stevens Isobel F
Department of Psychological Medicine, Christchurch School of Medicine and Health Sciences, New Zealand.
Aust N Z J Psychiatry. 2002 Jun;36(3):384-91. doi: 10.1046/j.1440-1614.2002.01026.x.
The first objective of this paper was to describe the pattern of remission, response and recovery in patients with major depression who were randomised for treatment with fluoxetine ornortriptyline. The second objective was to report on the demographic and diagnostic predictors of the response and recovery in these depressed patients.
One hundred and ninety-five patients with major depression were recruited for this outpatient study. After a detailed clinical and neurobiological evaluation patients were randomized to receive either fluoxetine or nortiptyline as an initial antidepressant treatment.
Of the 195 depressed patients randomised to treatment,154 completed an adequate 6-week trial of either fluoxetine or nortriptyline as their initial antidepressant. Of the 41 patients who did not complete an adequate trial the dropout rate was higher on those randomized to nortriptyline (p = 0.02). There was also an important interaction of drug and gender in determining dropouts in that women did not complete an adequate trial with nortriptyline and men did not complete an adequate trial with fluoxetine (p = 0.002). Of the 154 patients who completed an adequate 6-week antidepressant trial there were no significant differences in 6-week measures of depression severity or of percentage improvement. However, if we use an intention to treat analysis and dichotomise outcomes into response,remission or recovery; then recovery rates were significantly higher with fluoxetine than nortriptyline (p = 0.005). Using an intention to treat analysis fluoxetine was superior tonortriptyline in women, in those less than 25-years old, and in those with atypical depression. Independent of drug, those with chronic depressions had a poorer outcome.
In this sample of depressed patients randomized tonortriptyline or fluoxetine the change in depressive symptoms over 6 weeks were comparable between fluoxetine and nortriptyline. However,when we look at the more clinically important variable of recovery then fluoxetine was superior to nortriptyline. Predictors of a poorer response to nortriptyline were gender, young age and atypical depression. The results challenge traditional beliefs that selective serotonin re-uptake inhibitors (SSRIs) and tricyclic antidepressant have comparable efficacy.
本文的首要目的是描述重度抑郁症患者在随机接受氟西汀或去甲替林治疗后的缓解、反应和康复模式。第二个目的是报告这些抑郁症患者反应和康复的人口统计学及诊断预测因素。
195例重度抑郁症患者被纳入这项门诊研究。在进行详细的临床和神经生物学评估后,患者被随机分配接受氟西汀或去甲替林作为初始抗抑郁治疗。
在随机接受治疗的195例抑郁症患者中,154例完成了为期6周的充分试验,以氟西汀或去甲替林作为他们的初始抗抑郁药。在未完成充分试验的41例患者中,随机接受去甲替林治疗的患者脱落率更高(p = 0.02)。在决定脱落情况方面,药物和性别之间还存在重要的相互作用,即女性未完成去甲替林的充分试验,而男性未完成氟西汀的充分试验(p = 0.002)。在完成了为期6周充分抗抑郁试验的154例患者中,抑郁严重程度的6周测量值或改善百分比无显著差异。然而,如果我们采用意向性分析并将结果分为反应、缓解或康复;那么氟西汀的康复率显著高于去甲替林(p = 0.005)。采用意向性分析,氟西汀在女性、年龄小于25岁的患者以及非典型抑郁症患者中优于去甲替林。与药物无关,患有慢性抑郁症的患者预后较差。
在这个随机接受去甲替林或氟西汀治疗的抑郁症患者样本中,氟西汀和去甲替林在6周内抑郁症状的变化相当。然而,当我们观察更具临床重要性的康复变量时,氟西汀优于去甲替林。对去甲替林反应较差的预测因素是性别、年轻和非典型抑郁症。这些结果挑战了传统观念,即选择性5-羟色胺再摄取抑制剂(SSRI)和三环类抗抑郁药具有相当的疗效。